Concepedia

MAD2 activates IGF1R/PI3K/AKT pathway and promotes cholangiocarcinoma progression by interfering USP44/LIMA1 complex

Wangjie Jiang, Xiao Yang, Kuangheng Shi, Yaodong Zhang, Xiaoli Shi, Jifei Wang, Yuming Wang, Anlan Chenyan, Jijun Shan, Yirui Wang,

Oncogene · 2023 · 16 citations · 27 references

DOI

Concepts

References

27

Checkpoint inhibition of the APC/C in HeLa cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2

Valery Sudakin, Gordon K. Chan, Tim J. Yen · The Journal of Cell Biology · 2001 · 911 citations · Full text

, , +17

A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations

Yiqun Zhang, Patrick Kwok‐Shing Ng, Melanie H. Kucherlapati et al. · Cancer Cell · 2017 · 656 citations

, , +14

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial

David Malka, Pascale Cervera, Stéphanie Foulon et al. · The Lancet Oncology · 2014 · 414 citations · Full text

, , +14

SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Edgar Ben‐Josef, Katherine A. Guthrie, Anthony B. El-Khoueiry et al. · Journal of Clinical Oncology · 2015 · 409 citations

, , +17

Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities

Frank Stegmeier, Michael Rapé, Viji M. Draviam et al. · Nature · 2007 · 359 citations

, , +10